Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 70
Summary
- Conditions
- Acute Graft Versus Host Disease
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia
- Hematologic Malignancies
- Myelodysplastic Syndromes
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02743351
- Collaborators
- Not Provided
- Investigators
- Study Director: Sarah Cooley, MD Fate Therapeutics
Get Well Soon